Table 1.
Comparison of demographic data among the study groups
| Parameter | Dapagliflozin group, n = 200 | Insulin group, n = 100 |
Test of sig.
|
|
|
t/χ²
|
P value
|
|||
| Age in years | ||||
| mean ± SD | 56.84 ± 7.48 | 56.96 ± 9.29 | 0.121 | 0.904 |
| Range | 42–76 | 33–80 | ||
| Sex | ||||
| Male | 96 (48) | 44 (44) | 0.258 | 0.611 |
| Female | 104 (52) | 56 (56) | ||
| Smoking | ||||
| Yes | 59 (29.5) | 38 (38) | 2.202 | 0.137 |
| No | 141 (70.5) | 62 (62) | ||
| Contact with canal water | ||||
| Yes | 119 (59.5) | 59 (59) | 0.007 | 0.933 |
| No | 81 (40.5) | 41 (41) | ||
| Comorbidities1 | ||||
| Cardiac ischemia | 16 (8) | 11 (11) | 0.733 | 0.392 |
| HTN | 32 (16) | 21 (21) | 1.146 | 0.284 |
| Dyslipidemia | 16 (8) | 11 (11) | 0.733 | 0.392 |
| None | 160 (80) | 73 (73) | 1.883 | 0.170 |
| Child classification | ||||
| A | 56 (28) | 24 (24) | 4.599 | 0.100 |
| B | 81 (40.5) | 32 (32) | ||
| C | 63 (31.5) | 44 (44) | ||
| Causes of cirrhosis | ||||
| Unknown | 33 (16.5) | 14 (14) | 0.321 | 0.956 |
| HBV | 2 (1) | 1 (1) | ||
| HCV | 151 (75.5) | 78 (78) | ||
| Bilharziasis | 14 (7) | 7 (7) | ||
| Treatment of HCV Infection | ||||
| No | 49 (24.5) | 22 (22) | 0.329 | 0.849 |
| Interferon | 5 (2.5) | 2 (2) | ||
| DAAs | 146 (73) | 76 (76) | ||
| Diuretic dose change | ||||
| No change | 150 (75) | 18 (18) | 55.162 | < 0.00011 |
| Decreased dose | 0 (0) | 12 (12) | ||
| Stopped | 0 (0) | 8 (8) | ||
| Increased | 50 (25) | 41 (41) | ||
1
Some patients have more than 1 comorbidity.
Data are n (%) unless otherwise indicated. DAAs: Direct-acting antivirals; HCV: Hepatitis C virus; HTN: Hypertension; SD: Standard deviation.